Article
Many hospitalized patients with type 2 diabetes and mild hyperglycemia on admission can be managed with sliding scale insulin alone
January 7, 2022
Dr. Knees Clinical question: In patients with mild hyperglycemia on admission, can sliding scale insulin (SSI) alone be used for blood glucose (BG) control? Background: Prior randomized...
![1]()
News
Care via video teleconferencing can be as effective as in-person for some conditions
December 6, 2021
Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
News
Some diabetes drugs may lower risk of severe COVID-19 outcomes
October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
News
Age, C-reactive protein predict COVID-19 death in diabetes
September 29, 2021
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and improve survival.”
![1]()
News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
![1]()
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
![1]()
News
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
